Drug-induced hyperthermia with rhabdomyolysis in CLN3 disease

被引:4
|
作者
Savvidou, A. [1 ,2 ]
Jennions, E. [1 ,2 ]
Wikstrom, S. [3 ,4 ]
Olsson-Engman, M. [5 ]
Sofou, K. [1 ,2 ]
Darin, N. [1 ,2 ]
机构
[1] Univ Gothenburg, Inst Clin Sci, Sahlgrenska Acad, Dept Pediat, Gothenburg, Sweden
[2] Sahlgrens Univ Hosp, Dept Pediat, Reg Vastra Gotaland, Gothenburg, Sweden
[3] Cty Council Varmland, Ctr Clin Res & Educ, Varmland, Sweden
[4] Orebro Univ, Sch Med Sci, Orebro, Sweden
[5] Blekinge Hosp, Pediat Clin, Karlskrona, Sweden
关键词
Juvenile neuronal ceroid lipofuscinosis; CLN3; Neuroleptic malignant syndrome; Serotonin syndrome; Rhabdomyolysis; Neuroleptic malignant; NEUROLEPTIC MALIGNANT SYNDROME; SEROTONIN SYNDROME;
D O I
10.1016/j.ejpn.2022.06.007
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
CLN3 disease (MIM# 204200), the most prevalent of the neuronal ceroid lipofuscinoses (NCL), is an autosomal recessive disorder with juvenile onset characterized by blindness, epilepsy, dementia, psychiatric manifestations, and motor deterioration. Problems related to behavior, emotions and thought are among the main features. Antidepressant and antipsychotic drugs have been employed with variable results. Neuroleptic malignant syndrome (NMS) has previously been described in two patients with NCL, one with CLN3 disease and one with adult onset NCL of unclear genetic origin. Our aims were to describe the occurrence of drug-induced hyperthermia in pediatric patients with CLN3 disease from West and South Sweden and to delineate the range of associated clinical features. Our study identified four patients presenting with seven episodes of severe drug-induced hyperthermia and either NMS-like or Serotonin syndrome (SS)-like features. Possibly provoking drugs were risperidone, clozapine, olanzapine, haloperidol, quetiapine, and sertraline. The course was atypical, frequently prolonged, associated with rhabdomyolysis and status dystonicus, and resulted in the death of three of the patients. Our study points to a vulnerability to drug-induced hyperthermia in patients with CLN3 disease which we believe could be underreported. Interestingly the proposed pathophysiological mechanisms behind NMS and SS on one hand and CLN3 on the other hand seem to converge in a common mechanism involving dysregulation of the sympathetic nervous system.
引用
收藏
页码:74 / 78
页数:5
相关论文
共 50 条
  • [11] Identification of Modifier Genes of CLN3 Disease
    Lebrun, Anne-Helene
    Khosrawi, Parisa
    Storch, Stephan
    Pohl, Sandra
    Kilian, Dirk
    Streichert, Thomas
    Kohlschuetter, Alfried
    Ullrich, Kurt
    Braulke, Thomas
    Schulz, Angela
    EUROPEAN JOURNAL OF PEDIATRICS, 2010, 169 (03) : 391 - 391
  • [12] Farnesylation of Batten disease CLN3 protein
    Pullarkat, RK
    Morris, GN
    NEUROPEDIATRICS, 1997, 28 (01) : 42 - 44
  • [13] Quantitative Gait Analysis in CLN3 Disease
    Zimmerman, Grace
    Vierhile, Amy
    Adams, Heather
    Mink, Jonathan
    Augustine, Erika
    NEUROLOGY, 2020, 94 (15)
  • [14] A diagnostic confidence scheme for CLN3 disease
    Masten, Margaux C.
    Corre, Camille
    Paciorkowski, Alex R.
    Vierhile, Amy
    Adams, Heather R.
    Vermilion, Jennifer
    Zimmerman, Grace A.
    Augustine, Erika F.
    Mink, Jonathan W.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2021, 44 (06) : 1453 - 1462
  • [15] Timing of cognitive decline in CLN3 disease
    Kuper, Willemijn F. E.
    van Alfen, Claudia
    Rigterink, Roeliene H.
    Fuchs, Sabine A.
    van Genderen, Maria M.
    van Hasselt, Peter M.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2018, 41 (02) : 257 - 261
  • [16] Diagnostic Confidence for CLN3 Disease (Juvenile Batten Disease)
    Masten, M.
    Vierhile, A.
    Vermilion, J.
    Adams, H.
    Zimmerman, G.
    Corre, C.
    Augustine, E.
    Mink, J.
    ANNALS OF NEUROLOGY, 2021, 90 : S160 - S160
  • [17] Genotype-phenotype associations in CLN3 disease
    Masten, Margaux C.
    Vierhile, Amy
    Vermilion, Jennifer
    Adams, Heather R.
    Augustine, Erika F.
    Mink, Jonathan W.
    MOLECULAR GENETICS AND METABOLISM, 2021, 132 (02) : S69 - S70
  • [18] Mitochondrial abnormalities in CLN2 and CLN3 forms of Batten disease
    Dawson, G
    Kilkus, J
    Siakotos, AN
    Singh, I
    MOLECULAR AND CHEMICAL NEUROPATHOLOGY, 1996, 29 (2-3) : 227 - 235
  • [19] Diagnostic Confidence for CLN3 Disease (Juvenile Batten Disease)
    Masten, Margaux C.
    Vierhile, Amy
    Vermilion, Jennifer
    Adams, Heather R.
    Zimmerman, Grace A.
    Corre, Camille
    Augustine, Erika F.
    Mink, Jonathan W.
    NEUROLOGY, 2021, 96 (15)
  • [20] Repurposing of tamoxifen ameliorates CLN3 and CLN7 disease phenotype
    Soldati, Chiara
    Lopez-Fabuel, Irene
    Wanderlingh, Luca G.
    Garcia-Macia, Marina
    Monfregola, Jlenia
    Esposito, Alessandra
    Napolitano, Gennaro
    Guevara-Ferrer, Marta
    Scotto Rosato, Anna
    Krogsaeter, Einar K.
    Paquet, Dominik
    Grimm, Christian M.
    Montefusco, Sandro
    Braulke, Thomas
    Storch, Stephan
    Mole, Sara E.
    De Matteis, Maria A.
    Ballabio, Andrea
    Sampaio, Julio L.
    McKay, Tristan
    Johannes, Ludger
    Bolanos, Juan P.
    Medina, Diego L.
    EMBO MOLECULAR MEDICINE, 2021, 13 (10)